Lean Fatty Liver Disease
Cross-source consensus on Lean Fatty Liver Disease from 1 sources and 5 claims.
1 sources · 5 claims
Uses
Risks & contraindications
Evidence quality
Other
Highlighted claims
- Normal-BMI participants had substantially lower prevalence than the full study sample. — Comparison of the identification and practicability of non-invasive diagnostic indicators under NAFLD, MAFLD and MASLD in China: a cross-sectional study
- Lean hepatic steatosis is often underdiagnosed. — Comparison of the identification and practicability of non-invasive diagnostic indicators under NAFLD, MAFLD and MASLD in China: a cross-sectional study
- All six indicators identified fewer than half of patients in the normal BMI group. — Comparison of the identification and practicability of non-invasive diagnostic indicators under NAFLD, MAFLD and MASLD in China: a cross-sectional study
- Lean hepatic steatosis is associated with higher mortality and faster fibrosis progression than disease in overweight patients. — Comparison of the identification and practicability of non-invasive diagnostic indicators under NAFLD, MAFLD and MASLD in China: a cross-sectional study
- Current guidelines do not recommend routine NAFLD screening in lean populations. — Comparison of the identification and practicability of non-invasive diagnostic indicators under NAFLD, MAFLD and MASLD in China: a cross-sectional study